SCHEMBL3256775

SCHEMBL3256775

CCn1nnnc1CN(c1c(Cc2c(F)cccc2F)cccc1OC)S(=O)(=O)c1ccc(OC)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.38
HIF1A Q16665 4/20 0.35
EPAS1 Q99814 3/20 0.35
GAA P10253 1/20 0.34
PDE4A P27815 3/20 0.34
PDE4B Q07343 3/20 0.34
PDE4C Q08493 3/20 0.34
PDE4D Q08499 3/20 0.34
PTGER1 P34995 2/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 3/20 0.33
THRB P10828 1/20 0.33
EP300 Q09472 1/20 0.33
TP53 P04637 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.33
LMNA P02545 1/20 0.33
ALDH1A1 P00352 2/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3251397 0.86 PKM (0.40) KMT2AMAPTTP53LMNAALDH1A1
SCHEMBL3256140 0.84 MAPT (0.37) KMT2AHIF1AEPAS1GAAPDE4A
SCHEMBL3255545 0.79 KEAP1 (0.47) KMT2AGAAPTGER1MEN1MAPT
SCHEMBL3256115 0.79 MAPT (0.39) KMT2AHIF1AEPAS1GAAPDE4A
SCHEMBL3244402 0.78 MAPT (0.41) KMT2AGAAPTGER1MEN1MAPT
SCHEMBL3244840 0.77 PKM (0.41) HIF1AEPAS1PDE4APDE4BPDE4C
SCHEMBL8272874 0.77 HPGD (0.49) KMT2AGAAPTGER1MEN1MAPT
SCHEMBL3253856 0.76 ALDH1A1 (0.44) KMT2APDE4APDE4BPDE4CPDE4D
SCHEMBL3249587 0.76 HCRTR2 (0.47) PTGER1MAPTTP53ALDH1A1
SCHEMBL14107584 0.75 PTGER1 (0.50) KMT2AGAAPTGER1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776347-B1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2010-05-26 EP disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-7396958-B2 Sulphonamide derivatives, their preparation and their therapeutic application SANOFI AVENTIS (FR) 2008-07-08 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185136-A1 SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION HCRTR2, GIPR, SSTR2 KMT2A 1181/4885HIF1A 889/4885EPAS1 4184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.